Melinta Therapeutics Presentations at ECCMID Show Potential of Baxdela in Obese and other Challenging Patient Types

Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that the company and investigators will be presenting clinical evidence from the Baxdela™ (delafloxacin) clinical program at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Baxdela, an investigational fluoroquinolone, has completed Phase 3 testing and is the subject of a New Drug Application (NDA) currently under review at the U.S. Food and Drug Administration for the treatment of patients with serious hospital-treated skin infections (ABSSSI). The presentations at ECCMID include data from the complete Baxdela Phase 3 program, and demonstrate that Baxdela is comparable to vancomycin/aztreonam combination therapy in the treatment of patients with ABSSSI. Importantly, this comparability was demonstrated not only in the global study population, but in three key subgroups: patients with diabetes, renal impairment and obesity.